Precision Medicine in a Community Cancer Center: Pan-Cancer DNA/RNA Sequencing of Tumors Reveals Clinically Relevant Gene Fusions

Background: Gene fusions occur when two independent genes form a hybrid gene through genomic rearrangements, which often leads to abnormal expression and function of an encoded protein. In hematological and solid cancers, oncogenic fusions may be prognostic, diagnostic, or therapeutic biomarkers. Im...

Full description

Saved in:
Bibliographic Details
Published in:Biologics (Basel, Switzerland) Switzerland), 2023-08, Vol.3 (3), p.198-208
Main Authors: Darabi, Sourat, Zuazo, Carlos E., Braxton, David R., Eisenberg, Burton L., Demeure, Michael J.
Format: Article
Language:English
Subjects:
Biomarkers
Cancer
cancer genomics
Cancer therapies
Chromosomes
Collaboration
DNA sequencing
Genes
Genomics
Kinases
Lung cancer
Medical research
Metastasis
Mutation
oncogenic fusions
oncology precision medicine
Pediatrics
Precision medicine
Prostate cancer
Proteins
Response rates
Solid tumors
structural variants
tumor molecular profiling
Tumors
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background: Gene fusions occur when two independent genes form a hybrid gene through genomic rearrangements, which often leads to abnormal expression and function of an encoded protein. In hematological and solid cancers, oncogenic fusions may be prognostic, diagnostic, or therapeutic biomarkers. Improved detection and understanding of the functional implications of such fusions may be beneficial for patient care. Methods: We performed a retrospective analysis of our internal genomic database to identify known and novel gene fusions in different solid tumors seen in our community cancer center. We then investigated the clinical implications of the fusions we identified. Results: We identified 420 known oncogenic fusions and 25 unclassified gene fusions across twenty-six different cancer types. Of 420 fusion-positive tumors with known fusions, there were 366 unique gene fusions. Conclusions: About 10% of tumors investigated had oncogenic fusions, which supports the notion that comprehensive molecular profiling, including RNA sequencing, should be provided for patients with advanced cancers.
ISSN:2673-8449
2673-8449
DOI:10.3390/biologics3030011